In a statement, Safdar said the tragedy underscores the risks of bypassing the FDA approval process and argued that only stronger enforcement and sound policy, not broader compounding access, can protect patients
Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)
The honest framing: this isn't a fountain of youth, but for the right person it can help the body do more of what it did naturally when you were younger better sleep, better recovery, and a leaner, stronger baseline as part of a deliberate, monitored plan rather than a quick fix
Combining these effects generously suggests 5-8 pounds of potential weight loss, assuming optimal doses and individual responsiveness
High levels found in muscular tissue, the brain, and the heart